Efficacy and safety of tolcapone in levodopa‐treated Parkinson's disease patients with “wearing‐off” phenomenon: a multicentre, double‐blind, randomized, placebo‐controlled trial
- 1 July 1997
- journal article
- Published by Wiley in European Journal of Neurology
- Vol. 4 (4) , 333-341
- https://doi.org/10.1111/j.1468-1331.1997.tb00358.x
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Pharmacokinetic‐pharmacodynamic interaction between the COMT inhibitor tolcapone and single‐dose levodopa.British Journal of Clinical Pharmacology, 1995
- Acute Effects of COMT Inhibition on L-DOPA Pharmacokinetics in Patients Treated with Carbidopa and SelegilineClinical Neuropharmacology, 1995
- Acute Administration of Levodopa-Benserazide and Tolcapone, a COMT Inhibitor, in Parkinsonʼs DiseaseClinical Neuropharmacology, 1995
- Clinical Potential of Catechol-O-Methyltransferase (COMT) Inhibitors as Adjuvants in Parkinsonʼs DiseaseCNS Drugs, 1994
- Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's DiseaseNew England Journal of Medicine, 1988
- On‐off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamicsAnnals of Neurology, 1987
- Clinical Pharmacokinetics of Anti-Parkinsonian DrugsClinical Pharmacokinetics, 1987
- The pharmacology of Parkinson's disease: Basic aspects and recent advancesCellular and Molecular Life Sciences, 1984
- Problems associated with long-term levodopa treatment of Parkinson's diseaseActa Neurologica Scandinavica, 1983
- 3-0-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrierLife Sciences, 1975